SCHEMBL6618548

SCHEMBL6618548

c1ccc(COCc2cnc3cc4cn[nH]c4cc3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.43
▸ ROCK2 O75116 7/20 0.40
▸ GSK3B P49841 5/20 0.40
▸ ROCK1 Q13464 5/20 0.40
▸ JAK2 O60674 4/20 0.40
▸ AURKB Q96GD4 4/20 0.40
▸ CDC7 O00311 4/20 0.40
▸ CDK5 Q00535 3/20 0.40
▸ DYRK1A Q13627 3/20 0.40
▸ AURKA O14965 2/20 0.40
▸ DAPK3 O43293 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ PRKACA P17612 2/20 0.40
▸ CDK2 P24941 2/20 0.40
▸ MARK3 P27448 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ GSK3A P49840 2/20 0.40
▸ CDC42BPA Q5VT25 2/20 0.40
▸ CHUK O15111 1/20 0.40
▸ CHEK2 O96017 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6616873 1.00 MKNK1 (0.43) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL8117078 0.90 MKNK1 (0.38) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL8110676 0.87 ROCK2 (0.39) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL6618856 0.85 ROCK2 (0.49) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL6618464 0.85 ROCK2 (0.49) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL6616216 0.84 CYSLTR1 (0.46) GSK3BCDC7CDK5DYRK1AFGFR1
SCHEMBL6615880 0.84 CYSLTR1 (0.46) GSK3BCDC7CDK5DYRK1AFGFR1
SCHEMBL6617440 0.84 ROCK2 (0.49) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL6617033 0.84 ROCK2 (0.49) MKNK1ROCK2GSK3BROCK1JAK2
SCHEMBL6618578 0.83 CDC7 (0.43) MKNK1ROCK2GSK3BROCK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0779889-B1 PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE AVENTIS PHARMA INC (US) 2004-06-23 — — EP disclosed
US-5476851-A Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1995-12-19 — — US disclosed
Send feedback